Comparing Chiasma (CHMA) & The Competition
Chiasma (NASDAQ: CHMA) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Chiasma to similar companies based on the strength of its earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.
This is a breakdown of recent ratings and price targets for Chiasma and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Biopharmaceuticals” companies have a potential upside of 8.45%. Given Chiasma’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Chiasma has less favorable growth aspects than its rivals.
Earnings and Valuation
This table compares Chiasma and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Chiasma Competitors||$579.41 million||$241.76 million||-6.51|
Chiasma’s rivals have higher revenue and earnings than Chiasma. Chiasma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
50.4% of Chiasma shares are held by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 3.8% of Chiasma shares are held by insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Chiasma and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Chiasma has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Chiasma’s rivals have a beta of 1.28, meaning that their average share price is 28% more volatile than the S&P 500.
Chiasma rivals beat Chiasma on 9 of the 12 factors compared.
Chiasma Company Profile
Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company’s TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.
Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.